New combination treatment for untreated aggressive lymphoma

Plain-English translation of NCT07608978 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing polatuzumab vedotin combined with five other medications to treat a specific type of aggressive lymphoma (diffuse large B-cell lymphoma) that has not been treated before. The study will measure how well this medication combination works and whether it is safe. If the cancer responds well to treatment, you would then continue taking two of the medications for up to one year to help prevent the cancer from coming back.

This type of lymphoma can be difficult to treat, and doctors want to see if this new medication combination can improve how many patients get better and stay cancer-free longer. This treatment targets specific features of the cancer cells that may make it work better than current standard treatments.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with diffuse large B-cell lymphoma (a specific aggressive type) and have never had treatment for it
your cancer is at an intermediate or high risk level based on prognostic scoring
you are in good enough physical condition to tolerate chemotherapy (with a performance status score of 0, 1, or 2)
your heart is strong enough to handle the treatment (ejection fraction of 50% or higher)
you have a measurable tumor that can be seen on imaging

You likely don't qualify if…

you have an active infection of any kind, including tuberculosis
you are pregnant, breastfeeding, or planning to become pregnant within 12 months after treatment
you have had serious heart problems in the past 6 months, including a heart attack or unstable chest pain
you have significant liver disease, active hepatitis, or a positive test for hepatitis B or C
you have a history of a rare brain infection called progressive multifocal leukoencephalopathy or CNS lymphoma

What participation looks like

You would receive six cycles of treatment, with each cycle lasting 21 days. During each cycle, you would get intravenous (IV) infusions of the medication combination and take pills by mouth on specific days. Doctors would use CT or PET-CT scans to check how well the cancer is responding. If your cancer responds well, you would move to a maintenance phase where you continue taking two of the medications for up to one year, with regular check-ups to monitor your health and watch for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

New combination treatment for untreated aggressive lymphoma

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)